About Lyra Therapeutics
Lyra Therapeutics is a company based in Watertown (United States) founded in 2005 by George Whitesides and Robert Langer.. Lyra Therapeutics has raised $127.61 million across 12 funding rounds from investors including HHS, RA Capital and Perceptive Advisors. The company has 30 employees as of December 31, 2024. Lyra Therapeutics operates in a competitive market with competitors including Insulet, Decibel Therapeutics, TriSalus Life Sciences, Credence MedSystems and Akouos, among others.
- Headquarter Watertown, United States
- Employees 30 as on 31 Dec, 2024
- Founders George Whitesides, Robert Langer
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Lyra Therapeutics, Inc.
-
Annual Revenue
$1.53 M-1.54as on Dec 31, 2024
-
Net Profit
$-93.44 M-49.07as on Dec 31, 2024
-
EBITDA
$-60.26 M7.64as on Dec 31, 2024
-
Total Equity Funding
$127.61 M (USD)
in 12 rounds
-
Latest Funding Round
$50 M (USD), Post-IPO
Jun 09, 2023
-
Investors
HHS
& 9 more
-
Employee Count
30
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lyra Therapeutics
Lyra Therapeutics is a publicly listed company on the NASDAQ with ticker symbol LYRA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Lyra Therapeutics
Lyra Therapeutics has successfully raised a total of $127.61M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 12
- Last Round Post-IPO — $50.0M
-
First Round
First Round
(26 Oct 2011)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2023 | Amount | Post-IPO - Lyra Therapeutics | Valuation |
investors |
|
| Jan, 2020 | Amount | Series B - Lyra Therapeutics | Valuation | Perceptive Advisors | |
| Sep, 2018 | Amount | Series B - Lyra Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Lyra Therapeutics
Lyra Therapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, RA Capital and Perceptive Advisors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
US focused venture capital firm
|
Founded Year | Domain | Location | |
|
US focused seed to growth stage VC firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Lyra Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Lyra Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Lyra Therapeutics Comparisons
Competitors of Lyra Therapeutics
Lyra Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insulet, Decibel Therapeutics, TriSalus Life Sciences, Credence MedSystems and Akouos, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Wearable insulin infusion systems are developed for diabetes patients.
|
|
| domain | founded_year | HQ Location |
Medicines are developed to protect, repair, and restore hearing capacity.
|
|
| domain | founded_year | HQ Location |
Developer of drug delivery devices to treat cancers
|
|
| domain | founded_year | HQ Location |
Developer of smart devices for drug delivery
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies to restore and preserve hearing capabilities in genetically defined populations
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Lyra Therapeutics
Frequently Asked Questions about Lyra Therapeutics
When was Lyra Therapeutics founded?
Lyra Therapeutics was founded in 2005 and raised its 1st funding round 6 years after it was founded.
Where is Lyra Therapeutics located?
Lyra Therapeutics is headquartered in Watertown, United States.
Who is the current CEO of Lyra Therapeutics?
Maria Palasis is the current CEO of Lyra Therapeutics.
Is Lyra Therapeutics a funded company?
Lyra Therapeutics is a funded company, having raised a total of $127.61M across 12 funding rounds to date. The company's 1st funding round was a Series B of $29.5M, raised on Oct 26, 2011.
How many employees does Lyra Therapeutics have?
As of Dec 31, 2024, the latest employee count at Lyra Therapeutics is 30.
What is the annual revenue of Lyra Therapeutics?
Annual revenue of Lyra Therapeutics is $1.53M as on Dec 31, 2024.
What does Lyra Therapeutics do?
Lyra therapeutics is developing small molecule based therapeutics for ear, nose, and throat (ENT) diseases. The companys proprietary product platform is a transmucosal therapeutic system which comprises of drugs that target ear, nose, and throat diseases and administered through a polymeric matrix. The companys lead product candidate LYR-210 used against chronic rhinosinusitis is used to deliver a long-acting formulation of an approved steroid, mometasone furoate, deep into the sinonasal tissues. It has completed the Phase 1 clinical trials. It can be used in patients both with and without nasal polyps.
Who are the top competitors of Lyra Therapeutics?
Lyra Therapeutics's top competitors include Insulet, Decibel Therapeutics and TriSalus Life Sciences.
Is Lyra Therapeutics publicly traded?
Yes, Lyra Therapeutics is publicly traded on NASDAQ under the ticker symbol LYRA.
Who are Lyra Therapeutics's investors?
Lyra Therapeutics has 10 investors. Key investors include HHS, RA Capital, Perceptive Advisors, ArrowMark Partners, and Polaris Partners.
What is Lyra Therapeutics's ticker symbol?
The ticker symbol of Lyra Therapeutics is LYRA on NASDAQ.